Conditions: Diabetes Type 2 Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 437
Healthy volunteers: no

Brief summary:
This trial is conducted in Asia. The aim of the trial is to compare efficacy and safety of thrice daily versus twice daily NovoMix® 30 (Biphasic insulin aspart 30) in subjects with type 2 diabetes inadequately controlled with basal insulin.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: biphasic insulin aspart 30
Intervention descriptions: intervention 1: Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.

Protocol document:
Prot_SAP_000.pdf: 
&RYHU3DJHIRU3URWRFRO
 
Sponsor name: 
Novo Nordisk A/S 
NCT number 
NCT02582242 
Sponsor trial ID: 
BIAsp-4200 
Official title of study: 
A 24-week, Multinational, Multicentre, Randomised, Open 
Label, Parallel-group Treat-to-target Trial to Compare Efficacy 
and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 
(Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes 
Inadequately Controlled With Basal Insulin 
Document date: 
13 September 2017 
 









5HGDFWHGSURWRFRO
,QFOXGHVUHGDFWLRQRISHUVRQDOLGHQWLILDEOHLQIRUPDWLRQRQO\




